TEXAS HYPERTENSION CONTROL
Deadline: Friday, October 16th at 6:00 PM CT
These are abstracts which describe important current research advances and which have not been previously submitted for the Texas Hypertension Control Summit. The selection of abstracts will be based on scientific quality and novelty of research in public health or clinical science.
To submit an abstract for consideration:
1. You must be a clinical, healthcare, non-profit, public health professional, or a student with research interests in related areas.
2. Submit the abstract (500-word maximum) detailing your research and referencing all authors to Emily.Zhang@heart.org by Friday, October 16th, 2020 at 6:00 pm CT. If you have multiple presenters, the lead presenter should submit the abstract.
3. If your poster is selected, you will be notified by email by Monday, October 26, 2020.
Deadline to Submit: Friday, October 16, 2020 at 6:00 pm CT.
Presenters will be asked to submit a poster in PDF form in addition to their presentation slides. Please see below for deadlines of materials.
Timeline for Poster Presenters:
• After the October 16, 2020, 6:00 PM Central Time (CT) deadline, abstracts may not be revised in any way or resubmitted. Proofread abstracts carefully to avoid errors before submission.
• Abstract acceptance/non-acceptance status will be available in late-October. Please ensure that the email provided is accurate as all correspondences will be sent via email.
• All presentations and question-and-answer sessions will be conducted in English. Presenters may request assistance from the moderator who will repeat or rephrase questions from the audience or may ask a colleague in the audience to assist with translation.
• The presenting author of an accepted abstract must register for the virtual poster session. Details will be provided to presenters if the abstract is accepted.
• For questions regarding the submission guidelines, please contact Emily.Zhang@heart.org and reference "Poster Abstract Submission 2020" in the subject line.
Rules for Submitting an Abstract
• Submission of an abstract constitutes a commitment by the author(s) to present it if accepted. Failure to present, if not justified, will jeopardize future acceptance of abstracts for the Texas Hypertension Control Summit.
• There is no limit to the number of abstracts an investigator may submit. If selected, the presenter must be one of the co-authors listed.
Preparing an Abstract
An abstract must have a short, specific title (containing no abbreviations) that indicates the nature of the investigation.
• The submitting author is designated as the primary/presenting author. You may rearrange the order of the authors; however, always list the senior author last.
• If an author's name appears on more than one abstract, it must be identical on each abstract.
• Additions or deletions of author names are not permitted after Friday, October 16, 2020 6:00 PM CT. NO EXCEPTIONS.
• All authors’ names should be carefully reviewed for accuracy.
• Submit all abstracts in English.
• Authors should not "split" data to create several abstracts from one. If splitting is judged to have occurred, priority scores of related abstracts will be reduced.
• Abstracts containing identical or nearly identical data submitted from the same institution and/or individuals will be disqualified.
• Proofread abstracts carefully to avoid errors before submission.
• Describe briefly the objectives of the study unless they are contained in the title. Include a brief statement of methods if pertinent. State findings with enough detail to support conclusions. Abstracts should not describe research in which the chemical identity or source of the reagent is proprietary or cannot be revealed.
• Use generic drug names.
• Do not begin sentences with numerals.
• Standard abbreviations may be used without definition. Nonstandard abbreviations (kept to a minimum) must be placed in parentheses after the first use of the word or phrase abbreviated.
• Do not include references, credits or grant support.
• Do not include the names or personal information of any patient participating in the study or trial.
• Abstracts are limited to 500 words. This includes the text, but not the title or authors. All figure graphics (figures) and text-based graphics (tables) should be provided as 72 dpi, pre-sized jpg images, with a maximum width of 450 pixels. Only .jpg images should be submitted. Black-and-white digital images should be in grayscale mode. Color images should be saved in RGB color mode.
• Do not add paragraph breaks within the body of the abstract.
• Guidelines for abstract presentation will be provided to the presenting author of accepted abstracts in late-October via email.
NOTE: AHA’s Embargo Policies if you are planning to present your poster at upcoming American Heart Association’s scientific sessions. Details are here: https://newsroom.heart.org/newsmedia/embargo-policy